stockrow
Friday 6 November 2026
Export CRSP’s income statement to Excel — free account
CRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
49.92
1.36
+2.80%
Follow CRSP
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
2 | 2 | 3 | 2 |
| (30.18%) | (31.21%) | (26.09%) | (25.60%) | ||
| (25.81%) | (23.24%) | (19.28%) | (19.00%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(29.79%) | (23.45%) | (19.22%) | (20.29%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.85) | (4.18) | (3.85) | (3.89) | |
Free Cash Flow |
(345.93) | (401.18) | (371.32) | (376.71) | |
Capital Expenditures |
(0.91) | (1.21) | (1.74) | (2.08) | |
| Other line items | |||||
Cash ROIC |
(8.88%) | (8.29%) | (7.91%) | (8.36%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.01 | 0.01 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
10,856.38% | 9,192.03% | 2,095.48% | 1,212.81% | |
Selling, General and Administrative Expense of Revenue |
2,095.21% | 1,740.90% | 523.19% | 282.07% | |
Share Based Compensation of Revenue |
2,065.50% | 1,672.22% | 510.16% | 276.80% | |
Operating CF/Net income |
0.59 | 0.70 | 0.82 | 0.82 | |
Depreciation/Fixed assets |
0.17 | 0.17 | 0.17 | 0.18 | |
Capex/Depreciation |
(0.05) | (0.06) | (0.09) | (0.11) | |
Revenue per Share |
0.04 | 0.04 | 0.14 | 0.26 | |
Operating CF per Share |
(3.84) | (4.16) | (3.83) | (3.87) | |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.02) | |
Capex to Sales |
0.26 | 0.30 | 0.13 | 0.08 |
Columns are period end dates · fundamentals updated 6 Nov 2026